Galenband is developing a prescription cardiac telemetry system with the objective of delivering implantable-level arrhythmia detection rates via a wearable. Our system features a novel single-arm ECG which records diagnostic-level cardiac activity continuously for up to 90 days, with no recharging or pairing with a smart device necessary. Devices are provisioned remotely by clinicians using Galenband's cloud portal, and diagnostic-level data is automatically transmitted from device to portal via cellular networks. Galenband sends devices directly to patients after receiving a prescription, and clinicians can then use our auto-generated reports to inform the pathway of care.
Holter and Patch devices represent 95-98% of devices currently prescribed for cardiac monitoring. 60% of these prescriptions are for 1 day, but miss >60% of potentially stroke-causing cardiac events even when applied for 30 days. Achieving 90 days of continuous function with no surgery required, Galenband represents an accessible and convenient new tool enabling the timely application of treatments that can reduce stroke risk from cardiac conditions such as atrial fibrillation to baseline. Investing in Galenband means investing in a uniquely disruptive technology with the potential to wholly supplant incumbent solutions via a combination of advanced, yet easy-to-use, technology and a low-friction provisioning model.
Galenband is a platform technology with a sensor suite that reaches far beyond cardiac monitoring, and we hope you will join us as we address our initial indications and continue to expand into new markets.
